Abstract
Ethical Statement
Gaziantep İslam Bilim ve Teknoloji Üniversitesi Etik Kurul Komitesinden Etik kurul onayı alınmıştır.
Supporting Institution
YOK
Thanks
yok
References
- Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017.
- Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol. 2017;12(5):599-610.
- Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol. 2010;248(7):937-941.
- Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S. Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye (Lond). 2010;24(5):816-824.
- Badalà F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol. 2008;19(3):234-238.
- Seo JW, Park IW. Intravitreal bevacizumab for treatment of diabetic macular edema. Korean J Ophthalmol. 2009;23(1):17-22.
- Zayek M, Parker K, Rydzewska M, Rifai A, Bhat R, Eyal F. Bevacizumab for retinopathy of prematurity: 2-year neurodevelopmental follow-up. Am J Perinatol. 2021;38(11):1158-1166.
- Xu Y, Tan CS. Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol. 2017;37(2):325-332.
- Ahmed N, Rehman HU, Rafique M, Hamza MS, Mirza HA. Incidence of acute endophthalmitis after intravitreal bevacizumab injection at a tertiary care hospital in Lahore. Cureus. 2021;13(2):e13185.
- Bro T, Derebecka M, Jørstad ØK, Grzybowski A. Off-label use of bevacizumab for wet age-related macular degeneration in Europe. Graefes Arch Clin Exp Ophthalmol. 2020;258(3):503-511.
- Durand ML. Endophthalmitis. Clin Microbiol Infect. 2013;19(3):227-234.
- Li T, Sun J, Min J, et al. Safety of receiving anti-vascular endothelial growth factor intravitreal injection in office-based vs operating room settings: a meta-analysis. JAMA Ophthalmol. 2021;139(10):1080-1088.
- Artunay O, Yuzbasioglu E, Rasier R, Sengül A, Bahcecioglu H. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond). 2009;23(12):2187-2193.
- Karimi S, Fakhri N, Ansari I, Hassanpour K, Safi S. Incidence and management of acute endophthalmitis after intravitreal injection of bevacizumab. Int Ophthalmol. 2022;42(6):1827-1833.
- Pradhan E, Duwal S, Bajimaya S, Thapa R, Sharma S, Manandhar A. Acute endophthalmitis after intravitreal bevacizumab injections at the tertiary centre in Nepal. Nepal J Ophthalmol. 2018;10(19):107-110.
- Falavarjani KG, Modarres M, Hashemi M, et al. Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center. Retina. 2013;33(5):971-974.
- Khan P, Khan L, Mondal P. Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial. Indian J Ophthalmol. 2016;64(9):694-696.
- Hébert M, You E, Hammamji K, et al. Impact of patient face mask use on endophthalmitis after intravitreal anti-VEGF injections. Can J Ophthalmol. 2022;57(6):364-369.
- Bavinger JC, Yu Y, VanderBeek BL. Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab. Retina. 2019;39(10):2004-2011.
- Tanaka K, Shimada H, Mori R, et al. Safety measures for maintaining low endophthalmitis rate after intravitreal anti-vascular endothelial growth factor injection before and during the COVID-19 pandemic. J Clin Med. 2022;11(3):876.
- Sousa DC, Jalil A, Patton N, et al. Early pars plana vitrectomy in acute endophthalmitis: The Manchester Series. Ophthalmic Surg Lasers Imaging Retina. 2022;53(2):96-102.
Abstract
Aims: To investigate the incidence of acute endophthalmitis after intravitreal bevacizumab injections.
Methods: Patients who received treatment with intravitreal bevacizumab (1.25 mg/0.05 ml) injections for various indications between November 2020 and March 2022 were included in this retrospective study. The patients were followed up for 4 weeks after the injection in terms of acute endophthalmitis symptoms and signs.
Results: Acute endophthalmitis developed in 1 patient after 4593 intravitreal bevacizumab injections were administered to 1427 eyes of 1026 patients, and the incidence was found to be 0.0217%. The patient who developed acute endophthalmitis underwent pars plana vitrectomy and after 3 months, a significant improvement in visual acuity was observed.
Conclusion: Development of endophthalmitis postoperatively was found to be moderately low after intravitreal bevacizumab injection. It was concluded that following asepsis rules and optimal bevacizumab preparation conditions could further reduce this.
References
- Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017.
- Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol. 2017;12(5):599-610.
- Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol. 2010;248(7):937-941.
- Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S. Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye (Lond). 2010;24(5):816-824.
- Badalà F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol. 2008;19(3):234-238.
- Seo JW, Park IW. Intravitreal bevacizumab for treatment of diabetic macular edema. Korean J Ophthalmol. 2009;23(1):17-22.
- Zayek M, Parker K, Rydzewska M, Rifai A, Bhat R, Eyal F. Bevacizumab for retinopathy of prematurity: 2-year neurodevelopmental follow-up. Am J Perinatol. 2021;38(11):1158-1166.
- Xu Y, Tan CS. Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol. 2017;37(2):325-332.
- Ahmed N, Rehman HU, Rafique M, Hamza MS, Mirza HA. Incidence of acute endophthalmitis after intravitreal bevacizumab injection at a tertiary care hospital in Lahore. Cureus. 2021;13(2):e13185.
- Bro T, Derebecka M, Jørstad ØK, Grzybowski A. Off-label use of bevacizumab for wet age-related macular degeneration in Europe. Graefes Arch Clin Exp Ophthalmol. 2020;258(3):503-511.
- Durand ML. Endophthalmitis. Clin Microbiol Infect. 2013;19(3):227-234.
- Li T, Sun J, Min J, et al. Safety of receiving anti-vascular endothelial growth factor intravitreal injection in office-based vs operating room settings: a meta-analysis. JAMA Ophthalmol. 2021;139(10):1080-1088.
- Artunay O, Yuzbasioglu E, Rasier R, Sengül A, Bahcecioglu H. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond). 2009;23(12):2187-2193.
- Karimi S, Fakhri N, Ansari I, Hassanpour K, Safi S. Incidence and management of acute endophthalmitis after intravitreal injection of bevacizumab. Int Ophthalmol. 2022;42(6):1827-1833.
- Pradhan E, Duwal S, Bajimaya S, Thapa R, Sharma S, Manandhar A. Acute endophthalmitis after intravitreal bevacizumab injections at the tertiary centre in Nepal. Nepal J Ophthalmol. 2018;10(19):107-110.
- Falavarjani KG, Modarres M, Hashemi M, et al. Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center. Retina. 2013;33(5):971-974.
- Khan P, Khan L, Mondal P. Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial. Indian J Ophthalmol. 2016;64(9):694-696.
- Hébert M, You E, Hammamji K, et al. Impact of patient face mask use on endophthalmitis after intravitreal anti-VEGF injections. Can J Ophthalmol. 2022;57(6):364-369.
- Bavinger JC, Yu Y, VanderBeek BL. Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab. Retina. 2019;39(10):2004-2011.
- Tanaka K, Shimada H, Mori R, et al. Safety measures for maintaining low endophthalmitis rate after intravitreal anti-vascular endothelial growth factor injection before and during the COVID-19 pandemic. J Clin Med. 2022;11(3):876.
- Sousa DC, Jalil A, Patton N, et al. Early pars plana vitrectomy in acute endophthalmitis: The Manchester Series. Ophthalmic Surg Lasers Imaging Retina. 2022;53(2):96-102.
Details
| Primary Language | English |
|---|---|
| Subjects | Ophthalmology |
| Journal Section | Original Article |
| Authors | |
| Early Pub Date | January 7, 2024 |
| Publication Date | January 15, 2024 |
| Published in Issue | Year 2024 Volume: 7 Issue: 1 |
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/2316/file/4905/show
The indexes of the journal are ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, etc.
|
|
|
| |
|
|
|
|
The platforms of the journal are Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons, etc.
|
|
|
|
|
|
Our Journal using the DergiPark system indexed are;
Ulakbim TR Dizin, Index Copernicus, ICI World of Journals, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, OpenAIRE, MIAR, EuroPub, WorldCat (OCLC), DOAJ, Türkiye Citation Index, Türk Medline Index, InfoBase Index
Our Journal using the DergiPark system platforms are;
Journal articles are evaluated as "Double-Blind Peer Review".
Our journal has adopted the Open Access Policy and articles in JHSM are Open Access and fully comply with Open Access instructions. All articles in the system can be accessed and read without a journal user. https//dergipark.org.tr/tr/pub/jhsm/page/9535
Journal charge policy https://dergipark.org.tr/tr/pub/jhsm/page/10912
Editor List for 2022
Assoc. Prof. Alpaslan TANOĞLU (MD)
Prof. Aydın ÇİFCİ (MD)
Prof. İbrahim Celalaettin HAZNEDAROĞLU (MD)
Prof. Murat KEKİLLİ (MD)
Prof. Yavuz BEYAZIT (MD)
Prof. Ekrem ÜNAL (MD)
Prof. Ahmet EKEN (MD)
Assoc. Prof. Ercan YUVANÇ (MD)
Assoc. Prof. Bekir UÇAN (MD)
Assoc. Prof. Mehmet Sinan DAL (MD)
Our journal has been indexed in DOAJ as of May 18, 2020.
Our journal has been indexed in TR-Dizin as of March 12, 2021.
Articles published in the Journal of Health Sciences and Medicine have open access and are licensed under the Creative Commons CC BY-NC-ND 4.0 International License.